Estimation of Success Rate of Treatment of XDR-TB admitted in a Nodal DRTB Centre
Background: Extensively drug-resistant TB is still a serious challenge in India, and before the introduction of new anti-tuberculosis drugs these patients were treated with a conventional regimen for XDR-TB according to the guidelines of RNTCP at that time for almost 24 to 36 months.
Objective: To estimate the outcome of treatment of XDR-TB patients attended at our DRTB site and put under the conventional regimen during the period 2014-2017 according to protocol laid down by PMDT at that time i.e. 2014 to 2017.
Methods: In this retrospective study, we selected 41 patients admitted with XDR-TB, in our DRTB site from April 2014 to March 2017. We studied their treatment outcomes (cured, treatment completed, treatment failure, death, and treatment after default) 30 to 36 months after treatment initiation according to PMDT (2014 -2017).
Results: Among the 41 cases of XDR-TB that were included in the study 28 were male, 30 resided in rural areas and 28 had a BMI < 18.5 kg/m2. 13 (32%) patients were successfully treated but 21 (50%) patients died during the treatment and treatment failure happened in 6 (15%) patients. Patients with low BMI (< 18.5 kg/m2) had poor success rate (7%) and all the 21 patients who died during treatment, had low BMI.
Conclusion: The present study finds that only one in every three XDR-TB cases are successfully treated with conventional second-line antitubercular drugs and this finding is the same as found in the NTEP report. Nearly half of the patients die. The patients with low BMI respond worst.
How to cite this article:
Bhattacharya S, Bhattacharjee S, Das R, Dey A, Kar S. Estimation of Success Rate of Treatment of XDR-TB admitted in a Nodal DRTB Centre. J Commun Dis. 2022;54(1):31-35.
World Health Organization. Global tuberculosis report - WHO/CDS/TB/2018.20. Geneva, Switzerland: WHO; 2018.
Extensively drug resistant tuberculosis (XDR TB): recommendation from prevention and control. Weekly Epidemiol Rec. 2006 Nov;81:430-2. [PubMed] [Google Scholar]
Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systemic review and meta-analysis. Clin Infect Dis. 2010;51:6-14. [Google Scholar]
Central TB Division. Guidelines for Programmatic Management of Drug Resistant Tuberculosis in India. Ministry of Health and Family Welfare, Government of India; Mar 2021.
Central TB Division. Guideline on Programmatic Management of Drug Resistant TB (PMDT) in India. Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; 2012.
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006 Nov;368(9547):1575-80. [PubMed] [Google Scholar]
Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pe’rez Guzman C, Vargas MH, D’ Ambrosio L. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2013 Jul;42(1):169-79. [PubMed] [Google Scholar]
Kim DH, Kim HJ, Park SK, Kong SJ, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ. Treatment outcomes and long term survival in patients with extensively drug resistant tuberculosis. Am J Respir Crit Care Med. 2008 Nov;178(10):1075-82. [PubMed] [Google Scholar]
Copyright (c) 2022 Open Access
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.